A Phase 1, First-in-Human, Double-blinded, Randomized, Placebo-controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of an Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Healthy Flavivirus-Naïve and Flavivirus-Primed Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Aug 2017
At a glance
- Drugs Zika virus vaccine-Sanofi (Primary)
- Indications Zika virus infection
- Focus Adverse reactions; First in man
- 24 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 16 Feb 2017 Planned primary completion date changed from 1 May 2018 to 1 Feb 2019.
- 14 Jul 2016 New trial record